Developing Targeted and Immune Therapies for Colorectal Cancer Molecular Subtypes
Wafik El-Deiry, MD, PhD, FACP, and colleagues from Fox Chase Cancer Center recently collaborated with Caris Life Sciences®, a biotechnology company headquartered in Dallas-Fort Worth, Texas, to conduct three separate studies related to precision medicine, particularly in colorectal cancers. The findings were highlighted at the 2015 ASCO Annual Meeting.
“There is exciting progress in the treatment of colorectal cancer. Understanding the impact of genetic mutations on the potential likelihood of response to new treatments helps pave the way for defining their optimal use,” says El-Deiry, deputy cancer center director for translational research and co-leader of the Molecular Therapeutics Program at Fox Chase.
El-Deiry has collaborated with Caris Life Sciences® for several years on colorectal cancer genomic profiling.
Going to the 2015 ASH Annual Meeting?
Please join us at a special
Fox Chase Cancer Center reception
Saturday, December 5, 2015, 7:30–9:30 p.m.
Hyatt Regency Orlando
Register online at www.foxchase.org/ASH2015